Race and Mortality Risk After Radiation Therapy in Men Treated With or Without Androgen-Suppression Therapy for Favorable-Risk Prostate Cancer

被引:13
|
作者
Kovtun, Konstantin A. [1 ]
Chen, Ming-Hui [2 ]
Braccioforte, Michelle H. [3 ]
Moran, Brian J. [3 ]
D'Amico, Anthony V. [4 ]
机构
[1] Brigham & Womens Hosp, Dana Farber Canc Inst, Harvard Radiat Oncol Program, 75 Francis St, Boston, MA 02115 USA
[2] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA
[3] Prostate Canc Fdn Chicago, Westmont, IL USA
[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA
关键词
androgen-deprivation therapy; brachytherapy; mortality; prostate cancer; race; radiation therapy; RADICAL PROSTATECTOMY; DEPRIVATION THERAPY; FOLLOW-UP; RADIOTHERAPY; TRIAL;
D O I
10.1002/cncr.30224
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: African American (AA) men are more likely than non-AA men to have a comorbid illness that could interact with androgen-deprivation therapy (ADT) and shorten survival. This study assessed the impact that race had on the risk of all-cause mortality (ACM) and other-cause mortality (OCM) among men definitively treated for favorable-risk prostate cancer (PC). METHODS: Between 1997 and 2013, 7252 men with low-risk or favorable intermediate-risk PC were treated with brachytherapy with neoadjuvant ADT (n = 1501) or without neoadjuvant ADT (n = 5751) for a 4-month median duration. Cox and Fine-Gray multivariate regressions were used to analyze whether the risk of ACM and OCM increased among AA men versus non-AA men receiving ADT; adjustments were made for the age at brachytherapy, year of brachytherapy, cardiometabolic comorbidity status, risk group, and ADT treatment propensity score. RESULTS: After a median follow-up of 8.04 years, 869 men (12.0%) died: 48 (5.52%) of PC and 821 (94.48%) of other causes. There was a significant association between AA race and an increased risk of both ACM (adjusted hazard ratio [AHR], 1.77; 95% confidence interval [CI], 1.06-2.94; P = .028) and OCM (AHR, 1.86; 95% CI, 1.08-3.19; P = .024) among AA men versus non-AA men who received ADT but not among those who did not receive ADT (AHR for ACM, 1.33; 95% CI, 0.93-1.91; P = .12; AHR for OCM, 1.39; 95% CI, 0.96-2.02; P = .08). CONCLUSIONS: ADT use may shorten survival in AA men with favorable-risk PC; therefore, its reservation for the treatment of higher risk PC, for which level 1 evidence supports its use, should be considered. (C) 2016 American Cancer Society.
引用
收藏
页码:3608 / 3614
页数:7
相关论文
共 50 条
  • [31] Percent Positive Biopsy Cores and the Risk of Death from Prostate Cancer in Men Treated with Radiation and Androgen Deprivation Therapy
    Phillips, J.
    Chen, M.
    Zhang, D.
    Loffredo, M.
    Kantoff, P.
    D'Amico, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S155 - S155
  • [32] Comorbidity and the Receipt of Curative Therapy for Favorable-risk Prostate Cancer Prior to and Following the Publication of PIVOT
    Mihalcik, Stephen A.
    Chen, Ming-Hui
    Braccioforte, Michelle H.
    Moran, Brian J.
    D'Amico, Anthony V.
    EUROPEAN UROLOGY FOCUS, 2018, 4 (01): : 64 - 67
  • [33] Androgen Deprivation Therapy and the Risk of Death From Prostate Cancer Among Men With Favorable or Unfavorable Intermediate-Risk Disease
    Keane, Florence K.
    Chen, Ming-Hui
    Zhang, Danjie
    Moran, Brian J.
    Braccioforte, Michelle H.
    D'Amico, Anthony V.
    CANCER, 2015, 121 (16) : 2713 - 2719
  • [34] Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer
    Pollack, A
    Kuban, DA
    Zagars, GK
    UROLOGY, 2002, 60 (3A) : 22 - 30
  • [35] Comorbidity and the receipt of curative therapy for favorable-risk prostate cancer prior to and following the publication of PIVOT
    Mihalcik, Stephen A.
    Chen, Ming-Hui
    Braccioforte, Michelle H.
    Moran, Brian Joseph
    D'Amico, Anthony V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [36] Androgen suppression plus radiation therapy for prostate cancer
    Horwitz, EM
    Feigenberg, SJ
    Pollack, A
    Hanks, GE
    Uzzo, RG
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (17): : 2084 - 2085
  • [37] Androgen deprivation therapy and risk of diabetes mellitus in men undergoing androgen deprivation therapy for prostate cancer
    Kincade, MC
    Derweesh, IH
    Malcolm, J
    Lamar, KD
    Patterson, AL
    Kitabchi, AE
    Wake, R
    JOURNAL OF UROLOGY, 2006, 175 (04): : 41 - 41
  • [38] Intermediate versus short-course hormone therapy and mortality in men with high-risk prostate cancer treated with radiation therapy
    Nanda, Akash
    Chen, Ming-Hui
    Moran, Brian Joseph
    Braccioforte, Michelle H.
    D'Amico, Anthony Victor
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [39] Androgen deprivation therapy increased fracture risk in men with prostate cancer
    Krupski, TL
    Foley, KA
    Baser, O
    Long, SR
    Marcarios, D
    Oaks, T
    Litwin, MS
    JOURNAL OF UROLOGY, 2006, 175 (04): : 41 - 41
  • [40] Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy
    Palma, David
    Pickles, Tom
    CANCER, 2008, 112 (10) : 2322 - 2323